ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Description
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company’s principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). The Company has collaborated with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that may predict clinical response to Gencaro. ARCA’s product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2 receptors in the cardiac nervous system. The blocking of these receptors prevents binding with other molecules that serve to activate these receptors.
Address
SUITE 140, 11080 CIRCLEPOINT ROAD
WESTMINSTER, CO 80020
United States
WESTMINSTER, CO 80020
United States
Website
https://arcabio.com/Key stats and ratios
| Q1 (Mar '14) | 2013 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -48.23% | -68.38% |
| Return on average equity | -51.64% | -96.98% |
| Employees | 14 |
No comments:
Post a Comment